Inspire Medical Systems (NYSE:INSP) Shares Gap Down on Analyst Downgrade

Key Points

• Shares gapped down after Wells Fargo cut its price target from $70 to $56 and issued an equal-weight rating, with the stock opening at $47 (prior close $54.84) and heavy intraday volume.
• Although Inspire beat Q1 estimates (EPS $0.10 vs. consensus -$0.28; revenue $204.6M), management materially narrowed FY2026 guidance—EPS $0.75–$1.25 and revenue $825M–$875M—citing reimbursement/coding issues and a WISeR disruption, which drove the sell-off.
• Analyst sentiment has cooled with multiple price-target cuts and downgrades (e.g., Baird to $50), leaving a consensus rating of Hold (4 Buys, 15 Holds, 1 Sell) and placing further pressure on the shares.

Shares of Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) gapped down prior to trading on Tuesday after Wells Fargo & Company lowered their price target on the stock from $70.00 to $56.00. The stock had previously closed at $54.84, but opened at $47.00. Wells Fargo & Company currently has an equal weight rating on the stock. Inspire Medical Systems shares last traded at $45.5150, with a volume of 855,647 shares trading hands.

INSP has been the subject of several other reports. Robert W. Baird reduced their target price on Inspire Medical Systems from $63.00 to $50.00 and set a "neutral" rating for the company in a research note on Tuesday. Wolfe Research downgraded Inspire Medical Systems from an "outperform" rating to a "peer perform" rating in a research note on Friday, February 13th. Stifel Nicolaus reduced their target price on Inspire Medical Systems from $85.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 10th. Morgan Stanley set a $60.00 target price on Inspire Medical Systems in a research note on Wednesday, February 18th. Finally, Zacks Research downgraded Inspire Medical Systems from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 14th. Four research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Inspire Medical Systems has an average rating of "Hold" and a consensus target price of $94.11.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS (vs. consensus loss) and $204.6M revenue, topping Street expectations and showing modest year-over-year sales growth. This supports the company's underlying business strength. GlobeNewswire: Q1 Results
• Neutral Sentiment: Analyst note: Mizuho cut its price target from $70 to $55 but kept an "outperform" rating — the new target offers almost no upside versus the current price, so it is mixed (still favorable rating but lower conviction on upside). Benzinga
• Neutral Sentiment: Company materials and call transcript are available for investors reviewing management commentary and the details behind the guidance change. Earnings Call Summary (Yahoo)
• Negative Sentiment: Guidance cut — Inspire narrowed FY2026 EPS guidance to $0.75–$1.25 (street ~$1.99) and revenue to $825M–$875M (street ~$961M). Management cited reimbursement/coding issues and WISeR disruption as drivers of the downgrade, which materially reduces expected growth and margins. Seeking Alpha: Guidance & WISeR Disruption
• Negative Sentiment: Analyst downgrades/price-target cuts — Robert W. Baird cut its target to $50 and moved to "neutral"; Bank of America reaffirmed "neutral" with a $53 target. Those moves signal reduced analyst confidence and put further pressure on the shares. The Fly: Baird Note
• Negative Sentiment: Market reaction: coverage and headlines emphasizing the guidance cut and reimbursement uncertainty drove a sharp intraday sell-off (coverage noted a large single-day decline following the update). Yahoo Finance: Stock Reaction

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Xponance Inc. grew its holdings in Inspire Medical Systems by 2.9% in the 3rd quarter. Xponance Inc. now owns 4,177 shares of the company's stock valued at $310,000 after buying an additional 116 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock valued at $60,000 after buying an additional 130 shares in the last quarter. State of Wyoming grew its holdings in Inspire Medical Systems by 31.5% in the 4th quarter. State of Wyoming now owns 731 shares of the company's stock valued at $67,000 after buying an additional 175 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares in the last quarter. Finally, Apollon Wealth Management LLC grew its holdings in Inspire Medical Systems by 5.6% in the 1st quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company's stock valued at $206,000 after buying an additional 212 shares in the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Performance

The business has a fifty day simple moving average of $56.73 and a 200 day simple moving average of $79.64. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of 9.18, a price-to-earnings-growth ratio of 2.92 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. During the same period in the prior year, the firm posted $0.10 EPS. The company's revenue for the quarter was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, sell-side analysts forecast that Inspire Medical Systems, Inc. will post 1.82 earnings per share for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.